BioXcel Therapeutics Advances Process Development for BXCL501 Thin Film Formulation
02 mai 2019 08h36 HE
|
BioXcel Therapeutics, Inc.
Automated, scalable process developed for manufacturing clinical and commercial supply BXCL501 thin film architecture is proprietary and flexible for combination therapies Multiple subjects treated...
BioXcel Therapeutics to Host First Quarter 2019 Financial Results and Business Update
29 avr. 2019 17h17 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., April 29, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
BioXcel Therapeutics to Present at Upcoming Investor Conferences in April
03 avr. 2019 08h00 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., April 03, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that the Company will deliver corporate overview presentations at both the H.C...
BioXcel Therapeutics Showcases Data on BXCL701 in Combination with OX40 Agonist in Late-breaking Poster Presentation at AACR Annual Meeting
01 avr. 2019 08h03 HE
|
BioXcel Therapeutics, Inc.
Novel combination achieves synergistic anti-tumor effect and survival benefit Demonstrates BXCL701’s potential ability to bridge innate and adaptive immune systems Clinical Advisors Louis Weiner, MD...
BioXcel Therapeutics Files Clinical Trial Application for the Development of BXCL701 and Pembrolizumab in Neuroendocrine Prostate Cancer (tNEPC)
25 mars 2019 08h00 HE
|
BioXcel Therapeutics, Inc.
Expands global footprint for lead immuno-oncology program, BXCL701 Patient recruitment in US tNEPC study on-track; additional sites being activated Immuno-oncology Clinical Advisory Board expanded...
BioXcel Therapeutics to Present at 29th Annual Oppenheimer Healthcare Conference
13 mars 2019 16h01 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., March 13, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present...
BioXcel Therapeutics Announces Late Breaking Data Presentation at AACR 2019 Annual Meeting
11 mars 2019 08h00 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., March 11, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced that it will present a late breaking poster featuring data from a preclinical...
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2018 Quarterly Results and Provides Business Update
07 mars 2019 08h00 HE
|
BioXcel Therapeutics, Inc.
BXCL501 Pharmacokinetic (Bioavailability) and safety study on track to read out in second quarter 2019; initiation of Phase 2/3 Registration Trial expected in second half 2019 Human Proof of Concept...
BioXcel Therapeutics to Participate in Upcoming Investor Conferences in March
05 mars 2019 16h01 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., March 05, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present...
BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer
04 mars 2019 08h00 HE
|
BioXcel Therapeutics, Inc.
Clinical partnership to evaluate triple combination of BioXcel Therapeutics’ BXCL701, Nektar’s NKTR-214 and avelumab (Merck KGaA, Darmstadt, Germany and Pfizer) in pancreatic cancer Merck KGaA,...